Podcast: This Week in Managed Care—The $2 Million Gene Therapy and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication.

You may need to log in to the website to access this podcast.

iTunes

TuneIn

Stitcher

Spotify

Listen above or through one of these podcast services:

FDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients

Serious Health-Related Suffering to Nearly Double by 2060, Highlighting Need to Ramp Up Palliative Care Efforts

What We're Reading: FDA Grants Priority Review for Amarin's Vascepa; HHS Rule Challenged; Military Mental Health Proposal

Amarin's High-Dose Fish Oil Pill Cuts Total CV Event Risk 30% in Study

The American Journal of Managed Care®—May 2019

Open Doors to Primary Care Should Add a “Screen” to Reduce Low-Value Care

American Society of Clinical Oncology Annual Meeting 2019

Read more about the stories in this podcast: